Showing 654 results

Filters Content type: News, Editors' picks, About HIV Topic: New & experimental hepatitis C treatment

News and information about clinical trials and regulatory approval of new medications to treat hepatitis C.

New & experimental hepatitis C treatment

Phase 3 UNITY Trials Demonstrate High Cure Rates for Investigational, All-Oral Daclatasvir TRIO Fixed-Dose Combination in Genotype 1 Hepatitis C Patients, Including Those with Cirrhosis

Editor's pick
Bristol-Myers Squibb press release
10 November 2014
New & experimental hepatitis C treatment

ALLY Trial Demonstrates High Cure Rates for Investigational Daclatasvir and Sofosbuvir Combination among Genotype 3 Hepatitis C Patients

Editor's pick
Bristol-Myers Squibb press release
10 November 2014
New & experimental hepatitis C treatment

Achillion Reports 100% SVR12 in a Phase 2 Combination Study With ACH-3102 at the Liver Meeting 2014 (AASLD)

Editor's pick
Achillion press release
10 November 2014
New & experimental hepatitis C treatment

Merck's Four-Week Hepatitis C Regimen Fails to Top Gilead

Editor's pick
Bloomberg
10 November 2014
New & experimental hepatitis C treatment

Sofosbuvir/ledipasvir cures nearly all genotype 1 HCV for people with HIV co-infection

News
10 November 2014
Pharmaceutical industry

Bristol-Myers Plan to Widen Access to its Hep C Drug is Criticized

Editor's pick
Wall Street Journal
5 November 2014
Hepatitis C treatment

Bristol-Myers Squibb announces HCV global access plans

Editor's pick
Bristol-Myers Squibb press release
3 November 2014
New & experimental hepatitis C treatment

AbbVie 3D HCV regimen well-tolerated in PEARL trials

News
24 October 2014
New & experimental hepatitis C treatment

Sofosbuvir/ledipasvir safe and effective for genotype 1 HCV

News
20 October 2014
New & experimental hepatitis C treatment

IDWeek 2014: AbbVie 3D HCV Regimen Well-tolerated in PEARL Trials

Editor's pick
HIVandHepatitis.com
16 October 2014
New & experimental hepatitis C treatment

Fair Pricing Coalition Urges a Uniform Price for Curative Hepatitis C Treatment

Editor's pick
Fair Pricing Coalition
15 October 2014
Pharmaceutical industry

If AbbVie Discounts its Hep C Drug, Would Pricing Reach a Tipping Point?

Editor's pick
Wall Street Journal
15 October 2014
New & experimental hepatitis C treatment

U.S. Food and Drug Administration Approves Gilead’s Harvoni® (Ledipasvir/Sofosbuvir), the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C

Editor's pick
Gilead press release
10 October 2014
New & experimental hepatitis C treatment

In a surprise move, Bristol-Myers drops U.S. approval plans for hep C drug

Editor's pick
Fierce Biotech
7 October 2014
Pharmaceutical industry

J&J makes a splash in hep C with a $1.75B deal for Alios

Editor's pick
Fierce Biotech
1 October 2014
New & experimental hepatitis C treatment

After Patient's Death, Study Shows HCV Drug Cardiotoxic in 14 of 34 Treated Patients

Editor's pick
Medscape (requires registration)
29 September 2014
New & experimental hepatitis C treatment

Patent landscape for hepatitis issued by WHO

Editor's pick
Intellectual Property Watch
29 September 2014
New & experimental hepatitis C treatment

European CHMP Adopts Positive Opinion for Gilead’s Harvoni® (Ledipasvir/Sofosbuvir) for the Treatment of Chronic Hepatitis C Infection in Adults

Editor's pick
Gilead press release
29 September 2014
New & experimental hepatitis C treatment

AbbVie 3D hepatitis C regimen is well-tolerated in Phase 3 trials

Editor's pick
HIVandHepatitis.com
15 September 2014
Pharmaceutical industry

Gilead to raise price for new hepatitis C drug above $84000

Editor's pick
Reuters
15 September 2014
Hepatitis C treatment

MSF urges BMS to make daclatasvir accessible in low-and middle-income countries

Editor's pick
Pharmabiz
1 September 2014
New & experimental hepatitis C treatment

European Commission Approves Bristol-Myers Squibb’s Daklinza (daclatasvir) Across Multiple Genotypes for the Treatment of Chronic Hepatitis C Infection

Editor's pick
Bristol-Myers Squibb
27 August 2014
New & experimental hepatitis C treatment

PegLambda discontinued by BMS

Editor's pick
EATG
18 August 2014
New & experimental hepatitis C treatment

Achillion Achieves 100 Percent Sustained Virologic Response Rate (SVR4) From an Eight Week Phase 2 Trial Evaluating a Ribavirin-Free Regimen of ACH-3102 and Sofosbuvir for Genotype 1 HCV ("Proxy Study")

Editor's pick
Achillion press release
18 August 2014